Screening of a library of FDA-approved drugs identifies several enterovirus replication inhibitors that target viral protein 2C

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 2627-2638

  Ulferts, Rachel ^a,f   De Boer, S Matthijn ^a,g   Van Der Linden, Lonneke ^b   Bauer, Lisa ^a   Lyoo, Hey Rhyoung ^a   Maté, Maria J ^c,d   Lichière, Julie ^c,d   Canard, Bruno ^c,d   Lelieveld, Daphne ^e   Omta, Wienand ^e   Egan, David ^e   Coutard, Bruno ^c,d   Van Kuppeveld, Frank J M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CNRS   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g Institute for Translational Vaccinology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CAPPED RNA; CINCHOCAINE; FLUOXETINE; FORMOTEROL FUMARATE; GUANIDINE; PIRLINDOLE; PIRLINDOLE MESYLATE; PROTEIN INHIBITOR; PROTEIN VP2; RIBAVIRIN; UNCLASSIFIED DRUG; VIRAL PROTEIN 2C; VIRAL PROTEIN 2C INHIBITOR; VIRUS RNA; ZUCLOPENTHIXOL; 2C PROTEIN, VIRAL; CARBAZOLE DERIVATIVE; CARRIER PROTEIN; CLOPENTHIXOL; VIRAL PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL VIABILITY; CHLOROCEBUS; CONTROLLED STUDY; COXSACKIEVIRUS B3; DRUG APPROVAL; DRUG IDENTIFICATION; DRUG SCREENING; ENTEROVIRUS; ENTEROVIRUS A; ENTEROVIRUS B; ENTEROVIRUS C; ENTEROVIRUS D; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RHINOVIRUS; RNA REPLICATION; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; DRUG EFFECTS; GENETICS; HELA CELL LINE; METABOLISM;

ANTIVIRAL AGENTS; CARBAZOLES; CARRIER PROTEINS; CLOPENTHIXOL; DIBUCAINE; ENTEROVIRUS; FLUOXETINE; FORMOTEROL FUMARATE; HELA CELLS; HUMANS; RHINOVIRUS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84964938525     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02182-15     Document Type: Article

References (35)

1. George SN, Garcha DS, Mackay AJ, Patel ARC, Singh R, Sapsford RJ, Donaldson GC, Wedzicha JA. 2014. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur Respir J 44:87-96. http://dx .doi.org/10.1183/09031936.00223113.
2. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, Aniscenko J, Laza-Stanca V, Edwards MR, Slater L, Papi A, Stanciu LA, Kon OM, Johnson M, Johnston SL. 2011. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 183:734-742. http://dx.doi.org /10.1164/rccm.201006-0833OC.
3. Khetsuriani N, Kazerouni NN, Erdman DD, Lu X, Redd SC, Anderson LJ, Teague WG. 2007. Prevalence of viral respiratory tract infections in children with asthma. J Allergy Clin Immunol 119:314-321. http://dx.doi .org/10.1016/j.jaci.2006.08.041.
4. Thibaut HJ, De Palma AM, Neyts J. 2012. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol 83: 185-192. http://dx.doi.org/10.1016/j.bcp.2011.08.016.
5. van der Schaar HM, Leyssen P, Thibaut HJ, de Palma A, van der Linden L, Lanke KHW, Lacroix C, Verbeken E, Conrath K, Macleod AM, Mitchell DR, Palmer NJ, van de Poël H, Andrews M, Neyts J, van Kuppeveld FJM. 2013. A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase III-. Antimicrob Agents Chemother 57:4971-4981. http://dx .doi.org/10.1128/AAC.01175-13.
6. Arita M. 2014. Phosphatidylinositol-4 kinase III beta and oxysterolbinding protein accumulate unesterified cholesterol on poliovirusinduced membrane structure. Microbiol Immunol 58:239-256. http://dx .doi.org/10.1111/1348-0421.12144.
7. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2013. Oxysterol-binding protein family I is the target of minor enviroximelike compounds. J Virol 87:4252-4260. http://dx.doi.org/10.1128/JVI .03546-12.
8. Strating JRPM, van der Linden L, Albulescu L, Bigay J, Arita M, Delang L, Leyssen P, van der Schaar HM, Lanke KHW, Thibaut HJ, Ulferts R, Drin G, Schlinck N, Wubbolts RW, Sever N, Head SA, Liu JO, Beachy PA, De Matteis MA, Shair MD, Olkkonen VM, Neyts J, van Kuppeveld FJM. 2015. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep 10:600-615. http://dx.doi.org/10 .1016/j.celrep.2014.12.054.
9. Zuo J, Quinn KK, Kye S, Cooper P, Damoiseaux R, Krogstad P. 2012. Fluoxetine is a potent inhibitor of coxsackievirus replication. Antimicrob Agents Chemother 56:4838-4844. http://dx.doi.org/10 .1128/AAC.00983-12.
10. Yamaya M, Nishimura H, Nadine L, Kubo H, Nagatomi R. 2014. Formoterol and budesonide inhibit rhinovirus infection and cytokine production in primary cultures of human tracheal epithelial cells. Respir Invest 52:251-260. http://dx.doi.org/10.1016/j.resinv.2014.03.004.
11. Wessels E, Duijsings D, Notebaart RA, Melchers WJG, van Kuppeveld FJM. 2005. A proline-rich region in the coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-Golgi transport. J Virol 79:5163-5173. http://dx.doi.org/10.1128/JVI.79.8 .5163-5173.2005.
12. Lanke KHW, van der Schaar HM, Belov GA, Feng Q, Duijsings D, Jackson CL, Ehrenfeld E, van Kuppeveld FJM. 2009. GBF1, a guanine nucleotide exchange factor for Arf, is crucial for coxsackievirus B3 RNA replication. J Virol 83:11940-11949. http://dx.doi.org/10.1128 /JVI.01244-09.
13. Duke GM, Palmenberg AC. 1989. Cloning and synthesis of infectious cardiovirus RNAs containing short, discrete poly(C) tracts. J Virol 63: 1822-1826.
14. Reed L, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am J Epidemiol 27:493-497.
15. Riss TL, Moravec RA, Niles AL, Benink HA, Worzella TJ, Minor L. 2004. Cell viability assays. In Sittampalam GS, Gal-Edd N, Arkin M, Auld D, Austin C, Bejcek B, Glicksman M, Inglese J, Lemmon V, Li Z, McGee J, McManus O, Minor L, Napper A, Riss T, Trask OJ, Weidner J (ed), Assay guidance manual. Eli Lilly & Company, National Center for Advancing Translational Sciences, Bethesda, MD.
16. van Ooij MJM, Glaudemans DHRF, Heus HA, van Kuppeveld FJM, Melchers WJG. 2006. Structural and functional integrity of the coxsackievirus B3 oriR: spacing between coaxial RNA helices. J Gen Virol 87:689-695. http://dx.doi.org/10.1099/vir.0.81558-0.
17. De Palma AM, Heggermont W, Lanke K, Coutard B, Bergmann M, Monforte A-M, Canard B, De Clercq E, Chimirri A, Pürstinger G, Rohayem J, van Kuppeveld F, Neyts J. 2008. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol 82:4720-4730. http://dx.doi.org/10.1128/JVI .01338-07.
18. De Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Al-Tel TH, De Clercq E, van Kuppeveld F, Neyts J. 2009. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother 53:1850-1857. http://dx.doi.org/10.1128 /AAC.00934-08.
19. Lantez V, Dalle K, Charrel R, Baronti C, Canard B, Coutard B. 2011. Comparative production analysis of three phlebovirus nucleoproteins under denaturing or non-denaturing conditions for crystallographic studies. PLoS Negl Trop Dis 5:e936. http://dx.doi.org/10.1371/journal .pntd.0000936.
20. Ulferts R, van der Linden L, Thibaut HJ, Lanke KHW, Leyssen P, Coutard B, De Palma AM, Canard B, Neyts J, van Kuppeveld FJM. 2013. Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother 57:1952-1956. http://dx.doi.org/10 .1128/AAC.02084-12.
21. Medvedev AE, Veselovsky AV, Shvedov VI, Tikhonova OV, Moskvitina TA, Fedotova OA, Axenova LN, Kamyshanskaya NS, Kirkel AZ, Ivanov AS. 1998. Inhibition of monoamine oxidase by pirlindole analogues: 3DQSAR and CoMFA analysis. J Chem Inf Comput Sci 38:1137-1144. http: //dx.doi.org/10.1021/ci9802068.
22. van Kuppeveld FJ, Galama JM, Zoll J, Melchers WJ. 1995. Genetic analysis of a hydrophobic domain of coxsackie B3 virus protein 2B: a moderate degree of hydrophobicity is required for a cis-acting function in viral RNA synthesis. J Virol 69:7782-7790.
23. van Ooij MJM, Vogt DA, Paul A, Castro C, Kuijpers J, van Kuppeveld FJM, Cameron CE, Wimmer E, Andino R, Melchers WJG. 2006. Structural and functional characterization of the coxsackievirus B3 CRE(2C): role of CRE(2C) in negative- and positive-strand RNA synthesis. J Gen Virol 87:103-113. http://dx.doi.org/10.1099/vir.0 .81297-0.
24. van der Schaar HM, van der Linden L, Lanke KHW, Strating JRPM, Pürstinger G, de Vries E, de Haan CAM, Neyts J, van Kuppeveld FJM. 2012. Coxsackievirus mutants that can bypass host factor PI4KIII- and the need for high levels of PI4P lipids for replication. Cell Res 22:1576-1592. http://dx.doi.org/10.1038/cr.2012.129.
25. Papageorgiou N, Coutard B, Lantez V, Gautron E, Chauvet O, Baronti C, Norder H, de Lamballerie X, Heresanu V, Ferté N, Veesler S, Gorbalenya AE, Canard B. 2010. The 2C putative helicase of echovirus 30 adopts a hexameric ring-shaped structure. Acta Crystallogr D Biol Crystallogr 66:1116-1120. http://dx.doi.org/10.1107 /S090744491002809X.
26. Adams P, Kandiah E, Effantin G, Steven AC, Ehrenfeld E. 2009. Poliovirus 2C protein forms homo-oligomeric structures required for ATPase activity. J Biol Chem 284:22012-22021. http://dx.doi.org/10 .1074/jbc.M109.031807.
27. Vance LM, Moscufo N, Chow M, Heinz BA. 1997. Poliovirus 2C region functions during encapsidation of viral RNA. J Virol 71:8759-8765.
28. Klein M, Hadaschik D, Zimmermann H, Eggers HJ, Nelsen-Salz B. 2000. The picornavirus replication inhibitors HBB and guanidine in the echovirus-9 system: the significance of viral protein 2C. J Gen Virol 81: 895-901. http://dx.doi.org/10.1099/0022-1317-81-4-895.
29. Shimizu H, Agoh M, Agoh Y, Yoshida H, Yoshii K, Yoneyama T, Hagiwara A, Miyamura T. 2000. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J Virol 74:4146-4154. http://dx.doi.org/10.1128/JVI.74.9.4146-4154 .2000.
30. Xia H, Wang P, Wang G-C, Yang J, Sun X, Wu W, Qiu Y, Shu T, Zhao X, Yin L, Qin C-F, Hu Y, Zhou X. 2015. Human enterovirus nonstructural protein 2CATPase functions as both an RNA helicase and ATPindependent RNA chaperone. PLoS Pathog 11:e1005067. http://dx.doi .org/10.1371/journal.ppat.1005067.
31. Gorbalenya AE, Koonin EV, Wolf YI. 1990. A new superfamily of putative NTP-binding domains encoded by genomes of small DNA and RNA viruses. FEBS Lett 262:145-148. http://dx.doi.org/10.1016/0014-5793 (90)80175-I.
32. De Palma AM, Heggermont W, Leyssen P, Pürstinger G, Wimmer E, De Clercq E, Rao A, Monforte A-M, Chimirri A, Neyts J. 2007. Antienterovirus activity and structure-activity relationship of a series of 2,6- dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles. Biochem Biophys Res Commun 353:628-632. http://dx.doi.org/10.1016 /j.bbrc.2006.12.063.
33. Rossmann MG, He Y, Kuhn RJ. 2002. Picornavirus-receptor interactions. Trends Microbiol 10:324-331. http://dx.doi.org/10.1016/S0966-842X(02)02383-1.
34. Geller R, Vignuzzi M, Andino R, Frydman J. 2007. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev 21:195-205. http: //dx.doi.org/10.1101/gad.1505307.
35. Ford Siltz LA, Viktorova EG, Zhang B, Kouiavskaia D, Dragunsky E, Chumakov K, Isaacs L, Belov GA. 2014. New small-molecule inhibitors effectively blocking picornavirus replication. J Virol 88:11091-11107. http://dx.doi.org/10.1128/JVI.01877-14.